Eli Lilly’s Cyramza (ramucirumab) Receives FDA’s Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma

 Eli Lilly’s Cyramza (ramucirumab) Receives FDA’s Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma

Eli Lilly’s Emgality (galcanezumab-gnlm) Receives FDA’s Approval for Episodic Cluster Headache in Adults

Shots:

  • The approval is based on REACH‑2 study (NCT02435433) results assessing Cyramza (ramucirumab) + BSC vs PBO + BSC in 292 advanced HCC patients in the ratio (2:1) with alpha-fetoprotein (AFP) ≥ 400 ng/mL prior treated with sorafenib
  • The REACH-2 study (NCT02435433) resulted in meeting its 1EPs i.e median OS (8.5mos. vs 7.3mos.), mPFS (2.8 vs 1.6mos.), ORR (4.6% vs 1.1%)
  • Cyramza (ramucirumab, 8 mg/kg, q2w, IV) is a VEGFR2 antagonist and has received FDA’s approval as a monothx. or in combination with paclitaxel & docetaxel for advanced or m-gastric cancer & m-NSCLC respectively

Click here, Click here, to read full press release/ article | Ref: US FDA, Eli Lilly | Image: Bolon

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post